ID2 promotes tumor progression and metastasis in thyroid cancer

Background Inhibitor of DNA Binding 2 (ID2) plays a crucial role in tumor cell proliferation, invasion, metastasis, and stemness.

Aberrant ID2 expression is associated with poor prognosis in various cancers.

However, the specific function of ID2 in thyroid cancer remain unclear.

Method The TCGA database were utilized to explore the clinical relevance of ID2 in cancer.

GO, KEGG, and TIMER were employed to predict the potential roles of ID2 in cancer.

Functional analysis, including CCK-8, colony formation, transwell, wound healing, and sphere formation experiments, were conducted to determine the biological functions of ID2 in human cancers.

Western blot (WB), RT-qPCR, and immunohistochemical (IHC) analyses were used to investigate the relationship between ID2 and downstream targets.

Results Our study revealed significant overexpression of ID2 in various malignant tumor cells.

Knocking ID2 significantly inhibited cancer cell proliferation and invasion, while overexpressing ID2 enhanced these capabilities.

Additionally, ID2 mediates resistance of cancer cells to protein kinase B (or Akt) inhibitions.

Further WB and IHC experiments indicated that ID2 promotes the phosphorylation activation of phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway, thereby upregulating the expression of downstream proliferation, epithelial-mesenchymal transition (EMT), and stemness-related markers.

Conclusion We found that ID2 significantly promotes thyroid cancer cell proliferation, migration, EMT, and stemness through the PI3K/Akt pathway.

Moreover, ID2 plays a crucial role in regulating cancer immune responses.

It may serve as a potential biomarker for enhancing the efficacy of chemotherapy, targeted therapy, and immunotherapy against cancer.